MCL1 and acute myeloid leukemia: Recently, however, 4 agents (S64315124, AMG176125, AMG397126, and AZD5991127) with activity against MCL-1 entered phase 1 clinical trials as single agents in AML (NCT02979366128, NCT02675452129, NCT03465540130, NCT03218683131, with a view to combining with venetoclax (NCT03672695 132, NCT03797261133, NCT03218683131) or azacitidine (NCT02675452129), once dose-finding studies are completed.